Shielding advice updates

Find current advice in your nation for people considered clinically extremely vulnerable to Covid-19 (coronavirus).

Why do I no longer need to shield?

Since March 2020, at a time when the rate of Covid-19 (coronavirus) infection was high, shielding was recommended for people who were considered extremely vulnerable to the effects of coronavirus. This included anyone in active treatment for ovarian cancer.

Shielding programmes have been paused across the UK. This is because a lot more is known about the virus and what makes someone more or less vulnerable to Covid-19. More people have been vaccinated/are getting vaccinated and more treatments for Covid-19 are becoming available. 

What is my risk as someone who has a diagnosis of ovarian cancer?

It’s natural to worry about the risk of coronavirus to you and to want to know your level of risk. While it's not possible to predict anyone’s risk exactly, your healthcare team will be able to talk you through your level of risk and what that means for you.

What has changed in the shielding advice?

The shielding programme has now ended across all four nations. You're advised to follow the same restrictions as the general public. You may also want to take some extra precautions to keep yourself safe. 

What is the advice about returning to work?

In all four nations you're advised to work from home where possible. If you can't work from home you can go to work as long as your workplace has measures in place to make it Covid-secure (reduce the risk to employees).

Please remember that you can always call our support line on 020 7923 5475 (9am–5.30pm, Monday–Friday) and speak to one of our specialist nurses if you have any concerns or questions or just need someone to talk to. 


We make every effort to ensure that the information we provide is accurate. If you're concerned about your health, you should talk to your doctor. Target Ovarian Cancer cannot accept liability for any loss or damage resulting from any inaccuracy in this information or third-party information on websites we link to.

Last reviewed: 28 January 2022